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Abstract
Cognitive deficits have been regarded as one of the most significant clinical symptoms of depressive disorder.
Accumulating evidence has shown that apolipoprotein B (ApoB) levels, which are responsible for inducing
neurodegeneration, may be involved in cognitive deficits. This study examines cognitive deficits, and the
correlation of serum ApoB levels with cognitive deficits of depressive disorder. 90 depressive patients and 90
healthy controls with matched age and gender were recruited. Cognition was assessed using the Repeatable
Battery for the Assessment of Neuropsychological Status (RBANS). Serum ApoB levels in depressive patients
were measured by immunoturbidimetric method. Our results showed that depressive patients had lower
scores of cognition including RBANS total score and subscales of language and delayed memory (all, p <
0.001) than healthy controls after controlling for the variables. The differences in cognitive functions also
passed Bonferroni corrections. Serum ApoB levels were negatively correlated with delayed memory score in
depressive patients (r = −0.30, p = 0.01). Furthermore, stepwise multivariate regression analysis indicated that
serum ApoB levels independently contributed to delayed memory in depressive patients (t = −2.68, p = 0.01).
Our findings support that serum ApoB levels may be involved in delayed memory decline in depressive
patients. Depressive patients also experience greater cognitive deficits, especially in delayed memory and
language than healthy controls.
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Serum ApoB levels in depressive 
patients: associated with cognitive 
deficits
Li Hui1, Mei Han2, Xiang Dong Du1, Bao Hua Zhang3, Shu Chang He4, Tian Nan Shao1 & 
Guang Zhong Yin1
Cognitive deficits have been regarded as one of the most significant clinical symptoms of depressive 
disorder. Accumulating evidence has shown that apolipoprotein B (ApoB) levels, which are responsible 
for inducing neurodegeneration, may be involved in cognitive deficits. This study examines cognitive 
deficits, and the correlation of serum ApoB levels with cognitive deficits of depressive disorder. 90 
depressive patients and 90 healthy controls with matched age and gender were recruited. Cognition 
was assessed using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). 
Serum ApoB levels in depressive patients were measured by immunoturbidimetric method. Our 
results showed that depressive patients had lower scores of cognition including RBANS total score 
and subscales of language and delayed memory (all, p < 0.001) than healthy controls after controlling 
for the variables. The differences in cognitive functions also passed Bonferroni corrections. Serum 
ApoB levels were negatively correlated with delayed memory score in depressive patients (r = −0.30, 
p = 0.01). Furthermore, stepwise multivariate regression analysis indicated that serum ApoB levels 
independently contributed to delayed memory in depressive patients (t = −2.68, p = 0.01). Our findings 
support that serum ApoB levels may be involved in delayed memory decline in depressive patients. 
Depressive patients also experience greater cognitive deficits, especially in delayed memory and 
language than healthy controls.
Depressive disorder is one of the most common psychiatric disorders affecting millions of people worldwide1,2, 
and is closely associated with more frequent relapse, higher burden of illness, higher risk for suicide, and poorer 
quality of life3,4. Although depressive disorder mainly involved in mood disturbance, cognitive deficits have now 
been a well-established feature of this disorder5,6. The meta-analysis studies have indicated that cognitive deficits 
in depressive patients mainly appeared in the following domains, such as attention, memory, processing speed, 
executive functioning, and selective cognitive control7–9. Cognitive deficits in depressive patients were found 
to further lead to increased disability and mortality, and shortened life time10–13. Cognitive deficits should thus 
be considered a critical clinical and therapeutic target of depressive disorder. Furthermore, cognitive deficits in 
differing stages of depressive disorder have been reported. Recent studies have shown that cognitive functions in 
first-episode drug-free depressive patients were impaired in a Chinese population14,15. Current depressive patients 
have been found to have lower scores of all domains of cognitive functions than healthy controls, and there were 
significant differences in immediate memory and attention between previous depressive patients and healthy con-
trols16. Other studies have revealed that cognitive functions significantly declined in recurrent depressive patients 
with each successive episode of depression17,18. Cognitive deficits frequently persisted despite the remission of 
depressive episodes19. These studies have provided evidence that cognitive deficits in depressive patients may be 
pervasive and long-lasting. However, the etiology of cognitive deficits in depressive patients remains uncertain, 
which should be further investigated.
Serum apolipoprotein B (ApoB) is synthesized in the liver and small intestine rather than the brain, and is 
used for cholesterol transport in periphery20. Several human studies have indicated serum ApoB levels may be 
involved in cognitive dysfunction. A recent study has showed higher serum ApoB levels in older individuals with 
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amnestic mild cognitive impairments compared to healthy controls21. The variables of serum ApoB levels have 
been reported to be associated with cognitive changes prior to age 6522. Intriguingly, a post-mortem study has 
found that higher ApoB levels were significantly associated with higher brain Abeta43 levels that were involved 
in the dysfunctions of verbal learning, delayed verbal recall and response inhibition in neurodegenerative disor-
ders23,24. Several animal studies also have shown a significant association between ApoB and cognitive deficits. For 
example, ApoB overexpression in hAPPs1 mice alone induced memory decline compared to those in wild-type 
mice25. The addition of the ApoB transport domain to the secreted neprilysin was reported to be able to improve 
memory deficits in amyloid protein precursor transgenic model of Alzheimer’s disease26. These findings suggest 
that serum ApoB levels may influence cognitive functions in human and animal. However, no studies have exam-
ined the correlation between serum ApoB levels with cognitive deficits of depressive disorder. The purpose of the 
present study is to examine whether depressive patients have worse cognitive functions than healthy controls, and 
to further investigate whether serum ApoB levels contribute to cognitive deficits of depressive disorder.
Results
Clinical and Demographic Characteristics. Table 1 showed no significant difference in gender, age, and 
education between depressive patients and healthy controls (all p > 0.05). However, there were significant dif-
ferences in body mass index (BMI) (F = 23.72, p < 0.001), smoking status (χ 2 = 11.75, df = 1, p < 0.001), and 
suicide status (χ 2 = 81.29, df = 1, p < 0.001) between two groups. The mean and standard deviation (Mean ± SD) 
of age of illness onset, age of first hospitalization, self-rating depression scale (SDS) and self-rating anxiety scale 
(SAS) standards score, and serum ApoB levels in depressive patients were 31.30 ± 10.23 years, 33.67 ± 10.54 
years, 61.77 ± 12.73, 52.00 ± 12.14, and 0.86 ± 0.21 g/L. They had duration of illness for an average 50.70 ± 90.31 
months, with hospitalization number for a mean of 0.96 ± 0.92 time. The types of antidepressants included ser-
otonergic and noradrenergic reputake inhibitor (SNRI, 22.22%), selective serotonergic reuptake inhibitor (SSRI, 
58.89%), and never taking antidepressants (18.89%).
Main Findings. The Mean ± SD of the Repeatable Battery for the Assessment of Neuropsychological 
Status (RBANS) total and index scores of cognitive functions in 90 depressive patients and 90 healthy con-
trols were shown in Table 2. There were significant differences in cognitive functions including RBANS total 
score (75.17 ± 15.15 vs. 84.73 ± 13.15, F = 20.46, df = 1, p < 0.001) and subscales of language (76.70 ± 15.25 vs. 
96.36 ± 13.57, F = 83.42, df = 1, p < 0.001), and delayed memory (77.43 ± 19.02 vs. 95.97 ± 54.73, F = 9.21, df = 1, 
p = 0.003) between depressive patients and healthy controls. All these differences remained significant with low p 
values for RBANS total score (F = 19.56, df = 1, p < 0.001) and subscales of language (F = 58.21, df = 1, p < 0.001), 
and delayed memory (F = 7.72, df = 1, p = 0.006) between two groups after controlling for gender, age, education, 
BMI, smoking, and suicide status using MANOVA (Table 2). Furthermore, significant differences in RBANS total 
score and subscales of language, and delayed memory between two groups also passed Bonferroni corrections 
(all p < 0.05) (Table 2).
For depressive patients, correlation analysis showed a significant negative association between serum ApoB 
levels and delayed memory index score (r = − 0.30, df = 68, p = 0.01) (Fig. 1). Further stepwise multivari-
ate regression analysis showed that serum ApoB levels (ß = − 27.42, t = − 2.68, p = 0.01), education (ß = 1.83, 
t = 2.55, p = 0.01), and age of illness onset (ß = − 1.33, t = − 2.21, p = 0.03) independently contributed to delayed 
Variables
Depressive 
Patients (n = 90)
Healthy Controls 
(n = 90) F or χ2 P-value
Gender (male/female) 30/60 30/60 0.00 1.00
Age (years) 34.98 ± 10.78 34.98 ± 10.70 0.00 1.00
Education (years) 10.12 ± 3.34 9.74 ± 3.55 0.57 0.45
BMI (kg/m2) 21.62 ± 3.16 24.13 ± 3.70 23.72 <0.001
Smoking (smoker/nonsmoker) 8/82 26/64 11.75 <0.001
Suicide (attempter/no-attempter) 56/34 0/90 81.29 <0.001
Age of Illness Onset (years) 31.30 ± 10.23
Age of First Hospitalization (years) 33.67 ± 10.54
Duration of Illness (months) 50.70 ± 90.31
Number of Hospitalizations 0.96 ± 0.92
Types of Antidepressants
 SNRI 20 (22.22%)
 SSRI 53 (58.89%)
 Never Taking Antidepressants 17 (18.89%)
SDS Standard Score 61.77 ± 12.73
SAS Standard Score 52.0 ± 12.14
Apolipoprotein B (g/L) 0.86 ± 0.21
Table 1.  Clinical and demographic characteristics in depressive patients and healthy controls. Mean ± SD 
(standard deviation); BMI = body mass index; SNRI = serotonergic and noradrenergic reuptake inhibitor; 
SSRI = selective serotonergic reuptake inhibitor; SDS: self-rating depression scale; SAS: self-rating anxiety scale.
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memory score, which together accounted for 23.3% of the variance in delayed memory score of depressive disor-
der. However, serum ApoB levels were not found to be associated with RBANS total score and any other cognitive 
index scores in depressive patients (all p > 0.05).
Discussion
To the best of our knowledge, this is the first study to investigate the relationship between serum ApoB levels and 
cognitive functions in depressive patients. We find the effect of higher serum ApoB levels on delayed memory 
decline of depressive disorder. Depressive patients also have poorer cognitive functions than healthy controls, 
especially in delayed memory and language.
This study found cognitive functions were significantly impaired in depressive patients, which was consistent 
with other clinical studies that depressive patients experienced greater cognitive deficts5,27,28. Our finding was 
supported by several meta-analysis studies7–9. Another study adopting RBNAS for cognitive performance has 
shown that RBANS total score and five subscales of cognitive functions were significantly lower in depressive 
patients than healthy controls16. However, our results showed that there were significant differences in RBANS 
total score and subscales of delayed memory and language between depressive patients and healthy controls. The 
inconsistent findings between two studies could be due to demographic and clinical information differences, and 
ethnic background.
Previous studies have indicated that hippocampal formation could play a critical role in the regulation of 
cognitive functions29,30. A study has also found that reduced hippocampal volumes were associated with memory 
loss of depressive disorder31. The variables of hippocampus have been reported to contribute to language beyond 
its traditional role in memory in several recent studies32–35. These findings suggest that abnormal hippocam-
pal formation may be related to cognitive deficits of depressive disorder. Therefore, a further study on brain 
imaging-cognition in depressive patients should be performed, focusing on language and memory.
Interestingly, this study was the first to find that serum ApoB levels were negatively correlated with delayed 
memory decline of depressive disorder. The underlying mechanisms responsible for this could be that serum high 
ApoB levels are related to the dysfunctions of lipid peroxidation, malondialdehyde (MDA) and immune system 
that could been caused by oxidative stress and free radicals of depressive disorders that is associated with cogni-
tive decline36–39. Elevated levels of MDA have been reported to adversely affect the efficiency of delayed memory 
in patients with depressive disorder40. The postmortem and blood studies have shown that oxidative stress and 
cytokines played an important role in patients with depressive disorder41–43, which influenced cognitive func-
tions44. Several previous postmortem studies have indicated that oxidative stress was involved in the etiology of 
RBANS Score
Depressive Patients 
(n = 90)
Healthy Controls 
(n = 90) F P-valuea
P-valueb 
[Corrected]
Immediate Memory 75.92 ± 42.67 80.57 ± 17.21 3.81 0.053 0.318
Attention 92.82 ± 14.65 92.30 ± 18.44 0.04 0.837 1.000
Language 76.70 ± 15.25 96.36 ± 13.57 58.21 <0.001 <0.001
Visuospatial/Constructiona 85.29 ± 15.74 80.94 ± 14.37 0.84 0.361 1.000
Delayed Memory 77.43 ± 19.02 95.97 ± 54.73 7.72 0.006 0.036
Total Score 75.17 ± 15.15 84.73 ± 13.15 19.56 <0.001 <0.001
Table 2.  Comparisons of total and index scores of the RBANS between depressive patients and healthy 
controls. The nominally significant P-values (p < 0.05) are showed in bold. aP-values were analyzed by 
controlling for gender, age, education, BMI, smoking and suicide status. bP-values were further adjusted by 
Bonferroni correction.
Figure 1. Significantly negative correlation between Apo B and delayed memory index score in depressive 
patients (r = −0.3, df = 68, p = 0.01). 
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neurodegenerative disorders, which was significantly associated with cognitive decline45–50. Furthermore, serum 
ApoB change was significantly correlated with the decline of cognitive performance in older individuals with mild 
cognitive impairments36,51. Serum ApoB levels have been reported to be positively associated with brain Abeta43 
levels which influenced delayed memory of neurodegenerative disorders23,24. ApoB overexpression has been 
found to induce memory decline in hAPPs1 mice25. The fusion protein of ApoB transport domain and neprilysin 
was involved in improving memory deficits in animal model of Alzheimer’s disease26. These results support that 
serum ApoB levels, which are influenced by oxidative stress and free radicals, may contribute to delayed memory 
decline of depressive disorder.
Several limitations in this study should be noted. First, the association between serum ApoB levels and delayed 
memory in depressive patients was investigated by correlation and stepwise multivariate regression analyses. 
Therefore, the explanation of causal relationships was rather caution. Second, our samples were collected from 
Suzhou area, thus our findings may not be completely applicable to depressive patients in other cities of China. 
Finally, some other clinical information including residual symptom, recurrent episodes and remission status 
were not collected, which should be considered in statistical analysis as they can influence cognitive functions in 
depressive patients. The above factors could lead to deviation of our results. Therefore, a strictly designed study 
may be performed in the future to confirm our results.
In summary, we found that serum ApoB levels might play a crucial role in delayed memory decline in depres-
sive patients. Depressive patients experienced greater cognitive deficits than healthy controls, especially in delayed 
memory and language. However, this study should be viewed as a preliminary investigation, and further studies 
in larger, independent samples with case-control matching in different ethnicities are warranted to exclude the 
possibility of false-positive findings.
Methods
Study Population. This study was conducted between September 2014 and February 2016. Depressive 
patients (n = 90; male/female = 30/60) were recruited from the inpatient unit and outpatient clinic of the 
Affiliated Guangji Hospital of Soochow University. The catchment area of this hospital covered a population of 
approximately 9,060,000. Patients who met the following criteria were recruited to participate in the study: (a) 
age between 17 and 65 years; (b) diagnosis of unipolar depression according to the Diagnostic and Statistical 
Manual of Mental Disorders, Forth (DSM–IV); (c) received education for at least 4 years; and (d) provided writ-
ten informed consent and were able to take part in the cognitive assessment. Diagnoses were performed for 
each patient by two independent experienced clinical psychologists and confirmed using the Structured Clinical 
Interview for DSM-IV.
Healthy controls (n = 90; male/female = 30/60) were recruited from the employees of the Affiliated Guangji 
Hospital of Soochow University. Current mental status and personal or family history of mental disorders were 
assessed using unstructured interviews. None of the healthy controls presented a personal or family history of 
psychiatric disorders.
Depressive patients and healthy controls with matched age and gender were Han Chinese from the Suzhou 
area. All subjects were in good physical health, and any subjects with abnormalities were excluded, such as 
schizoaffective disorders, dementia, neurodegenerative and neurological disorder, cardiovascular disease, cere-
brovascular disease, infections, cancer, diabetes, hypertension, hyperlipidemia, and pregnant. Neither depressive 
patients nor healthy controls were experiencing drug or alcohol abuse/dependence, which was determined by the 
laboratory urine tests.
Informed consent was obtained before subjects were recruited. This protocol employed was approved by the 
Clinical Research Ethics Committee of the Affiliated Guangji Hospital of Soochow University, and all experiments 
were carried out in accordance with the approved guidelines and regulations.
Clinical Variables. A detailed questionnaire including a complete medical history, physical examination, and 
medical and psychological conditions was obtained from all subjects. Additional information was collected from 
available medical records.
Cognitive functions were measured using the RBANS (Form A)52. The RBANS was composed of 12 subtests 
that were used to calculate 5 age-adjusted index scores and a total score. The test indices were immediate memory 
(composed of listing learning and story memory tasks), attention (composed of digit span and coding tasks), lan-
guage (composed of picture naming and semantic fluency tasks), visuospatial/constructional (composed of figure 
copy and line orientation tasks), and delayed memory (composed of list recall, story recall, figure recall, and list 
recognition tasks). The RBANS was previously translated into Chinese, and its clinical validity and test-retest reli-
ability were established in healthy controls and psychiatric disorder in our previous study53. To ensure consistency 
and reliability of rating, the two clinical psychologists simultaneously attended a training session for standard-
izing their use of the RBANS prior to the start of the study. Thereafter, they maintained an intraclass correlation 
coefficient of 0.93 on the RBANS at the repeated assessments.
Measurement of Serum ApoB Levels. Serum samples from 70 depressive patients were collected 
between 7 and 9 AM following an overnight fast. HITACHI 7180 automatic biochemistry analyzer (Hitachi 
High-Technologies Corporation, Japan) was used for measuring serum ApoB levels by immunoturbidimetric 
method using a commercially available kit (Medical System Biotechnology, Ningbo, China). A full description 
of this method has been reported in a previous study54. Serum samples were assayed by a technician blind to the 
clinical situation. Each assay was run in duplicate. Inter- and intra-assay variation coefficients were 4% and 1.5%, 
respectively.
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Statistical Analysis. Group comparisons on the clinical and demographic data used Student’s t-tests or 
analysis of variance (ANOVA) for continuous variables and chi-square for categorical variables. The RBANS total 
and index scores of cognitive functions were compared between depressive patients and healthy controls using 
ANOVA. When the significant differences in cognitive functions were found between two groups using ANOVA, 
multivariate ANOVA (MANOVA) will further analyze these differences in cognitive functions, with gender, age, 
education, BMI, smoking, and suicide status as the covariates. Bonferroni corrections were applied to each test 
to adjust for multiple testing. Relationships between serum ApoB levels and the scores of cognitive deficits of 
depressive disorder were measured with Pearson’s product moment correction coefficients. Stepwise multivariate 
analysis using the scores of cognitive deficits of depressive disorder as dependent variables was used to investigate 
the impact of serum ApoB levels and other variables including gender, age, education, BMI, smoking and suicide 
status, age of illness onset, age of first hospitalization, duration of illness, number of hospitalization, the types of 
antidepressants, SDS and SAS standard score. SPSS version 17.0 was used to do all statistical analysis. Continuous 
data were presented as Mean ± SD and all p values were 2 tailed at the significance level of < 0.05.
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